In a significant stride for its complex drug portfolio, Biocon has secured USFDA approval for Liraglutide injections, a key GLP-1 therapy for treating diabetes and obesity. While the drug represents an earlier generation of metabolic treatments compared to the blockbuster "twin-titans" Semaglutide (Ozempic/Wegovy) and Tirzepatide (Mounjaro), Biocon's leadership views it as a critical foundation for their vertically integrated expansion into the $100 billion-plus global metabolic market.
Speaking on the development, Siddharth Mittal, CEO and MD of Biocon, noted that while Liraglutide's peak global sales have tapered from $5 billion to under $1 billion, the generic opportunity remains robust.
"We are already selling this product in select European markets and will launch in the US soon," Mittal stated. He estimates the revenue potential for Biocon's generic version could reach $100 million, cited by limited competition and the company's "bench-to-bedside" capability. As a vertically integrated player, Biocon manufactures its own drug substance, drug product, and delivery devices-a trifecta Mittal believes will be the company's primary differentiator.
ALSO READ: Novo Will Slash US List Prices For Wegovy, Ozempic Next Year
The India Strategy: A War of Attrition
Despite the domestic buzz surrounding GLP-1 therapies, Biocon is taking a cautious, export-led approach toward India. The Indian market is bracing for an intense price war, with monthly treatment costs rumored to drop as low as Rs 5,000.
"India will see a huge price war. It is not a game of a few months; it is here to stay," Mittal cautioned. Because Biocon divested its branded India business to Eris Lifesciences two years ago, it now operates through partners domestically. Consequently, the company is prioritizing markets in the West and emerging territories where margins are more attractive and clinical trial requirements for exports are already met.
ALSO READ: Ozempic Changing How You Trade? The Hidden Link Between GLP1 Drugs And Risk Taking
Navigating the 2031 Horizon
The broader GLP-1 landscape is shifting rapidly. While Liraglutide provides immediate momentum, the industry is eyeing 2031, the year Semaglutide patents expire in the US and Europe. Mittal expects the GLP-1 category to eventually contribute "a couple of hundred million dollars" to Biocon's top line as these larger patent cliffs approach.
However, the path is not without volatility. Innovator pricing strategies have already shrunk the projected total addressable market (TAM) from $150 billion to under $100 billion in the last year, suggesting that even before generics flood the market, price erosion is a factor.
Beyond the lab, Biocon is navigating geopolitical friction in global shipping routes. While raw material supplies from China remain steady, the company has pivoted from sea to air freight to avoid disruptions in the Strait of Hormuz. "We are air-shipping instead of sea-shipping," Mittal confirmed. While airlifting is roughly three times more expensive, Mittal downplayed the financial sting, noting the impact on margins would likely be less than 1%.
ALSO READ: Ozempic Patent Ends On March 20 And A Generic Deluge Is Coming Forcing Prices To Fall
Essential Business Intelligence, Continuous LIVE TV, Sharp Market Insights, Practical Personal Finance Advice and Latest Stories — On NDTV Profit.
